Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history

References

• FajtMLWenzelSEDevelopment of new therapies for severe asthmaAllergy Asthma Immunol Res201791314
   Web of Science ®Google Scholar
• BarnesPJJonssonBKlimJBThe costs of asthmaEur Respir J19969463642
   Web of Science ®Google Scholar
• ChungKFManaging severe asthma in adults: lessons from the ERS/ATS guidelinesCurr Opin Pulm Med2015211815
   Web of Science ®Google Scholar
• MooreWCMeyersDAWenzelSEIdentification of asthma phenotypes using cluster analysis in the Severe Asthma Research ProgramAm J Respir Crit Care Med20101814315323
   Web of Science ®Google Scholar
• HaldarPPavordIDShawDECluster analysis and clinical asthma phenotypesAm J Respir Crit Care Med20081783218224
   Web of Science ®Google Scholar
• BourdinAMolinariNVachierIPrognostic value of cluster analysis of severe asthma phenotypesJ Allergy Clin Immunol2014134510431050
   Web of Science ®Google Scholar
• Xolair 2017 [updated 2017] Available from: http://www.xolair.com/allergic-asthma/hcp
   Google Scholar
• HalwaniRSultanaAVazquez-TelloAJamhawiAAl-MasriAAAl-MuhsenSTh-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthmaJ Asthma Epub201732
   Web of Science ®Google Scholar
• FahyJVType 2 inflammation in asthma: present in most, absent in manyNat Rev Immunol20151515765
   Web of Science ®Google Scholar
• ChippsBELanierBMilgromHOmalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experienceJ Allergy Clin Immunol2017139514311444
   Web of Science ®Google Scholar
• SamitasKDelimpouraVZervasEGagaMAnti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectivesEur Respir Rev201524138594601
   Google Scholar
• HolowkaDSilDTorigoeCBairdBInsights into immunoglobulin E receptor signaling from structurally defined ligandsImmunol Rev200721726927917498065
   PubMed Web of Science ®Google Scholar
• GalliSJTsaiMIgE and mast cells in allergic diseaseNat Med2012185693704
   Web of Science ®Google Scholar
• MacGlashanDWJrBochnerBSAdelmanDCDown-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibodyJ Immunol1997158314381445
   Google Scholar
• MitchellPDEl-GammalAIO’ByrnePMAnti-IgE and biologic approaches for the treatment of asthmaHandb Exp Pharmacol201723713115227864676
   PubMedGoogle Scholar
• LedfordDBusseWTrzaskomaBA randomized multicenter study evaluating Xolair persistence of response after long-term therapyJ Allergy Clin Immunol2017140162.e2169.e227826098
   PubMed Web of Science ®Google Scholar
• ChanMAGigliottiNMDotsonALRosenwasserLJOmalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cellsClin Transl Allergy201332924004581
   PubMedGoogle Scholar
• BousquetJCabreraPBerkmanNThe effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy2005603302308
   Web of Science ®Google Scholar
• HumbertMBusseWHananiaNAOmalizumab in asthma: an update on recent developmentsJ Allergy Clin Immunol Pract201425525.e1536.e1
   Google Scholar
• HananiaNAWenzelSRosénKExploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA studyAm J Respir Crit Care Med20131878804811
   Web of Science ®Google Scholar
• BerryABusseWWBiomarkers in asthmatic patients: has their time come to direct treatment?J Allergy Clin Immunol2016137513171324
   Web of Science ®Google Scholar
• PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialLancet201238065165922901886
   PubMed Web of Science ®Google Scholar
• PizzichiniEPizzichiniMMEfthimiadisADolovichJHargreaveFEMeasuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral bloodJ Allergy Clin Immunol1997994539544
   Web of Science ®Google Scholar
• PriceDBRigazioACampbellJDBlood eosinophil count and prospective annual asthma disease burden: a UK cohort studyLancet Respir Med2015311849858
   Web of Science ®Google Scholar
• MansurAHSrivastavaSMitchellVSullivanJKasujeeILongterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safetyRespir Med2017124364328284319
   PubMed Web of Science ®Google Scholar
• CasaleTBChippsBERosénKResponse to omalizumab using patient enrichment criteria from trials of novel biologics in asthmaAllergy Epub2017831
   Web of Science ®Google Scholar
• BusseWSpectorSRosénKWangYAlpanOHigh eosinophil count: a potential biomarker for assessing successful omalizumab treatment effectsJ Allergy Clin Immunol20131322485.e11486.e11
   Google Scholar
• RankMAOchkurSILewisJCNasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophiliaAllergy2016714567570
   Web of Science ®Google Scholar
• WrightKBioactive paper will revolutionize point-of-care diagnostics2013 Available from: http://dailynews.mcmaster.ca/article/bioactive-paper-will-revolutionize-point-of-care-diagnosticsAccessed October 28, 2017
   Google Scholar
• DweikRABoggsPBErzurumSCAn official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels FENO for clinical applicationsAm J Respir Crit Care Med20111845602615
   Web of Science ®Google Scholar
• MehtaVStokesJRBerroARomeroFACasaleTBTime-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthmaAnn Allergy Asthma Immunol200910313137
   Web of Science ®Google Scholar
• PetskyHLKewKMChangABExhaled nitric oxide levels to guide treatment for children with asthmaCochrane Database Syst Rev201611CD01143927825189
   PubMed Web of Science ®Google Scholar
• PetskyHLKewKMTurnerCChangABExhaled nitric oxide levels to guide treatment for adults with asthmaCochrane Database Syst Rev20169CD01144027580628
   PubMed Web of Science ®Google Scholar
• PijnenburgMWBakkerEMLeverSHopWCDe JongsteJCHigh fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic childrenClin Exp Allergy2005357920925
   Web of Science ®Google Scholar
• HaldarPBrightlingCEHargadonBMepolizumab and exacerbations of refractory eosinophilic asthmaN Engl J Med200936097398419264686
   PubMed Web of Science ®Google Scholar
• CorrenJWoodRAPatelDEffects of omalizumab on changes in pulmonary function induced by controlled cat room challengeJ Allergy Clin Immunol20111272398405
   Web of Science ®Google Scholar
• TajiriTMatsumotoHGonYUtility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthmaAllergy2016711014721479
   Web of Science ®Google Scholar
• FitzpatrickAMTeagueWGMeyersDAHeterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research ProgramJ Allergy Clin Immunol20111272382389.e1e13
   Web of Science ®Google Scholar
• PelaiaGCanonicaGWMatucciAPaoliniRTriggianiMPaggiaroPTargeted therapy in severe asthma today: focus on immunoglobulin EDrug Des Devel Ther201711197987
   PubMed Web of Science ®Google Scholar
• BergerWGuptaNMcAlaryMFowler-TaylorAEvaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthmaAnn Allergy Asthma Immunol2003912182188
   Web of Science ®Google Scholar
• MilgromHBergerWNayakATreatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)Pediatrics2001108E3611483846
   PubMed Web of Science ®Google Scholar
• KornSHaaslerIFliednerFMonitoring free serum IgE in severe asthma patients treated with omalizumabRespir Med20121061494150022884459
   PubMed Web of Science ®Google Scholar
• TeachSJGillMATogiasAPreseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbationsJ Allergy Clin Immunol20151361476148526518090
   PubMed Web of Science ®Google Scholar
• PaganinFMangiapanGProustALung function parameters in omalizumab responder patients: an interesting tool?Allergy Epub2017518
   Web of Science ®Google Scholar
• AbrahamIAlhossanALeeCSKutbiHMacDonaldK‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic reviewAllergy20167159361026644231
   PubMed Web of Science ®Google Scholar
• KallieriMPapaioannouAIPapathanasiouENtontsiPPapirisSLoukidesSPredictors of response to therapy with omalizumab in patients with severe allergic asthma: a real life studyPostgrad Med201712959860428427296
   PubMed Web of Science ®Google Scholar
• MenzellaFGaleoneCFormisanoDReal-life efficacy of omalizumab after 9 years of follow-upAllergy Asthma Immunol Res201794368372
   Web of Science ®Google Scholar
• GarciaGMagnanAChironRA proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthmaChest201314441141923579324
   PubMed Web of Science ®Google Scholar
• LambrechtBNHammadHThe immunology of asthmaNat Immunol20151614556
   Web of Science ®Google Scholar
• Kupryś-LipińskaIMolińskaKKunaPThe effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthmaPneumonol Alergol Pol2016844232243
   Google Scholar